Clorazepate Dipotassium
Brand names: Clorazepate Dipotassium
At a glance
- Medicare prescriptions, 2024
- 64,553
- Medicare drug cost
- $5.5M
- Average cost per prescription
- $84.50
- Clinicians who prescribed it
- 3,590
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Clorazepate dipotassium tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (See WARNINGS and PRECAUTIONS). The use of benzodiazepines, including clorazepate dipotassium tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 25.0%
- Internal Medicine 21.0%
- Psychiatry 18.0%
- Nurse Practitioners 10.5%
- Neurology 9.1%
- Psychiatric Nurse Practitioners 3.5%
- General Practice 3.3%
- Physician Assistants 3.1%
- Cardiology 1.1%
- Child & Adolescent Psychiatry 0.8%
- Geriatric Medicine 0.7%
- Child Neurology 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 40% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico −33%
- California −37%
- Florida −38%
- Louisiana −38%
- Tennessee −40%
- Georgia (smallest change) −45%
- South Carolina (smallest change) −45%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 3.75 mg | blue round tablet, 8 mm, scored to split in 2 | |
| 7.5 mg | orange round tablet, 8 mm, scored to split in 2 | C |
| 15 mg | pink round tablet, 8 mm, scored to split in 2 | C 21 |
Aurolife Pharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 3.75 mg | blue round tablet, 7 mm, scored to split in 2 | M 30 |
| 7.5 mg | orange round tablet, 8 mm, scored to split in 2 | M 40 |
| 15 mg | white round tablet, 9 mm, scored to split in 2 | M 70 |
Clinical Solutions Wholesale, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 3.75 mg | purple round tablet, 9 mm, scored to split in 2 | T 45 |
| 7.5 mg | orange round tablet, 9 mm, scored to split in 2 | T 46 |
| 15 mg | pink round tablet, 9 mm, scored to split in 2 | T 47 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | pink round tablet, 9 mm, scored to split in 2 | T 47 |
Sun Pharmaceutical Industries, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 3.75 mg | purple round tablet, 9 mm, scored to split in 2 | T 45 |
| 7.5 mg | orange round tablet, 9 mm, scored to split in 2 | T 46 |
| 15 mg | pink round tablet, 9 mm, scored to split in 2 | T 47 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Apr 2024 · Aurobindo Pharma USA Inc. · Class II
Discoloration: Dotted and yellow spots on tablets
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.